Clinical Trials Sponsored by Eisai China Inc.

Total 861 results

Eisai China Inc.

Completed

Efficacy and Safety of Cinitapride Tablets in the Treatment of Mild to Moderate Functional Dyspepsia

Dyspepsia

China
Eisai China Inc.

Completed

Drug Use Survey (DUS) of Triple Therapy (Methycobal (MBL)+ Myonal (MYO)+ Non-steroidal Anti-inflammatory Drags (NSAID)) on the Symptom Relief of Lumbar DDD in China

Lumbar Disc Degenerative Disease

China
Changhai Hospital
Eisai China Inc.

Completed

A Study to Evaluate the Efficacy of Teprenone On Chinese Patients With Chronic Non-Atrophic Erosive Gastritis

Chronic Erosive Gastritis

China
Eisai Korea Inc.

Completed

A Study of Pariet to Prevent Gastric and Duodenal Ulcer Associated With Low-aspirin in Korean Participants With a History of Gastric and Duodenal Ulcer

Duodenal Ulcer | Stomach Ulcer

Korea, Republic of
Eisai Korea Inc.

Completed

Open-label, Multi-center Trial of Zonisamide as Adjunctive Therapy in Patients With Uncontrolled Partial Epilepsy

Epilepsy

Korea, Republic of
Eisai Korea Inc.

Completed

Comparative Study of Zonisamide and Carbamazepine as an Initial Monotherapy: Efficacy and Safety Evaluation

Epilepsy

Korea, Republic of
Eisai Korea Inc.

Completed

Alzheimer's Disease Long-term Follow-up Study (ALF Study)

Alzheimer's Disease

Korea, Republic of
Eisai Korea Inc.

Completed

A Study of Fycompa (Perampanel) in Korean Participants

Epilepsy

Korea, Republic of
Eisai Korea Inc.

Completed

Study in Patients With Moderated to Severe Rheumatoid Arthritis Who Have Failed to Combination Therapy of Conventional Disease-modifying Antirheumatic Drugs (cDMARDs) to cDMARD Plus ANti-TNF Versus cDMARDs in Real World (HUMAN)

Arthritis, Rheumatoid

Korea, Republic of
Eisai Korea Inc.

Completed

Study to Observe the Change in Microbiome in Human Derived Sample and the Relation With Clinical Response Before and After the Anti-TNF Treatment in IBD Patients (ETERNITY)

Inflammatory Bowel Disease

Korea, Republic of
Eisai Korea Inc.

Completed

A Plan on Investigation and Collection of Aricept Safety Information With a Dose Increase on Alzheimer's Disease Patients (AID)

Alzheimer's Disease

Korea, Republic of
Eisai Korea Inc.

Completed

Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer (ESKIMO)

Breast Cancer | Breast Neoplasms

Korea, Republic of
Eisai Korea Inc.

Terminated

Correlation Between Regional Brain Volume and Response to Donepezil Treatment in AD Patients

Alzheimer's Disease

Korea, Republic of
Eisai Korea Inc.

Completed

Low and High Dose Zonisamide in Children as Monotherapy

Epilepsy

Korea, Republic of
Eisai Korea Inc.

Completed

A Study of Lenvatinib in Combination With Pembrolizumab in Korean Patients

Carcinoma | Renal Cell Carcinoma | Endometrial Neoplasms | Endometrium

Korea, Republic of
Eisai Korea Inc.

Completed

A Study of Lenvima (Lenvatinib) in Korean Unresectable Hepatocellular Carcinoma (uHCC) Participants

Carcinoma, Hepatocellular | Liver Neoplasms

Korea, Republic of
Eisai Korea Inc.

Completed

A Study for Tecfidera (Dimethyl Fumarate) Capsules in Korean Participants With Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis, Relapsing-remitting

Korea, Republic of
Eisai Korea Inc.

Completed

Symbenda Post-Marketing Surveillance (PMS)

Lymphoma, Non-Hodgkin | Multiple Myeloma | Lymphocytic Leukemia

Korea, Republic of
Eisai Korea Inc.

Completed

A Multi-national Study to Identify Treatment Discontinuation Rate in de Novo Alzheimer's Disease Patients Who Have Been Newly Prescribed With Donepezil (Aricept) in Asia (ADOS) (ADOS)

Alzheimer's Disease

China, Taiwan, Korea, Republic of, Singapore, Thailand, Philippines
Eisai Korea Inc.

Completed

A Multicenter Comparative Trial of Zonisamide and Topiramate as Initial Monotherapy in Untreated Epilepsies

Epilepsy

Korea, Republic of
Eisai Korea Inc.

Recruiting

A Study of Jyseleca Tablet (Filgotinib Maleate) in Korean Participants

Arthritis, Rheumatoid | Colitis, Ulcerative

Korea, Republic of
Eisai Korea Inc.

Recruiting

A Post Marketing Surveillance Study of Equfina Tablet 50 Milligram (mg)

Parkinson Disease

Korea, Republic of
Eisai Korea Inc.

Active, not recruiting

A Study to Evaluate the Efficacy and Safety of Perampanel Monotherapy in Untreated Participants With Focal Onset Seizures With or Without Focal to Bilateral Tonic-clonic Seizures

Epilepsy

Korea, Republic of
Eisai Korea Inc.

Completed

A Study to Evaluate the Efficacy and Safety of Safinamide Mesilate as Add-on Therapy to Levodopa in Parkinson's Disease Participants With Motor Fluctuation in South Korea

Parkinson Disease

Korea, Republic of
Eisai Korea Inc.

Completed

The Clinical Response of Choline Acetyltransferase and Apolipoprotein Epsilon Gene Polymorphisms to Donepezil in Alzheimer's Disease

Alzheimer's Disease

Korea, Republic of
Eisai Korea Inc.

Completed

Post-Marketing Surveillance of Lenvima in Korean Patients

Differentiated Thyroid Carcinoma (DTC)

Korea, Republic of
Eisai Korea Inc.

Completed

A Study to Evaluate Alzheimer's Disease Conversion Rate Differences Between High-risk Mild Cognitive Impairment (MCI) and Low-risk MCI in a Real World Setting (CONCORDE)

Mild Cognitive Impairment

Korea, Republic of
Eisai Korea Inc.

Completed

Halaven Post-Marketing Surveillance (PMS)

Breast Cancer

Korea, Republic of
Eisai Korea Inc.

Completed

Trial Evaluating the Efficacy and Safety of Perampanel Added to Monotherapy in Participants With Partial Onset Seizures With or Without Secondary Generalization

Epilepsy

Korea, Republic of
Eisai Korea Inc.

Completed

A Study to Investigate the Efficacy and Safety of Eribulin in Korean Breast Cancer Participants

Locally Advanced or Metastatic Breast Cancer

Korea, Republic of
Eisai Korea Inc.

Completed

Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease (SAVE)

Alzheimer's Disease

Korea, Republic of
Eisai Limited

Not yet recruiting

A Community-Based Screening Program to Identify Participants at High Risk for Amyloid Pathology

Alzheimer's Disease

United States
Eisai Limited

Completed

An Open-Label, Multicenter, Phase 1/2 Study of Poly(ADP-Ribose) Polymerase (PARP) Inhibitor E7449 as Single Agent in Subjects With Advanced Solid Tumors or With B-cell Malignancies and in Combination With Temozolomide (TMZ) or With Carboplatin and Paclitaxel in Subjects With Advanced Solid Tumors

Ovarian Cancer | Triple Negative Breast Cancer | Malignant Solid Tumour | Advanced Melanoma | B-cell Malignancy, Low-grade

United Kingdom
Eisai Limited

Completed

A Study to Investigate Dosage, Effectiveness, and Safety of Perampanel When Used as First Add-on Therapy in Participants >=12 Years With Partial Onset Seizures With or Without Secondary Generalization or With Primary Generalized Tonic-Clonic Seizures Associated With Idiopathic Generalized Epilepsy

Idiopathic Generalized Epilepsy | Partial Onset Seizures | Generalised Tonic-Clonic Seizures

France, Spain, Italy, Denmark, Germany, Portugal, Russian Federation
Eisai Limited

Suspended

A Study to Evaluate the Relative Bioavailability of E7386 Following Oral Administration of Targeted Release (TR) Tablets Compared to an E7386 Immediate Release (IR) Tablet in Healthy Adult Participants

Healthy Volunteers

United Kingdom
Eisai Limited

Completed

A 12-Day Randomized, Blinded, Vehicle and Active Comparator-Controlled Study to Determine the Efficacy and Safety of Six Concentrations of Topical E6201 Gel in Subjects With Psoriasis Vulgaris

Psoriasis Vulgaris

Germany
Eisai Inc.
Eisai Limited

Completed

E7389 Versus Treatment of Physician's Choice in Patients With Locally Recurrent or Metastatic Breast Cancer

Breast Cancer

Russian Federation, Italy, Belgium, Canada, South Africa, France, United States, Switzerland, Argentina, Australia, Austria, Brazil, Croatia, Czechia, Hungary, Poland, Spain
Eisai Limited

Completed

An Open-label, Multicenter, Multiple Dose, Phase 1 Study to Establish the Maximum Tolerated Dose of E7389 Liposomal Formulation in Patients With Solid Tumors

Solid Tumors

United Kingdom
Eisai Limited

Completed

Patient Registry of Intrathecal Pain Management in Europe for Prialt (Ziconotide Intrathecal Infusion) and Alternative Drugs for the Management of Severe, Chronic Pain. (PRIME)

Pain Management | Severe Chronic Pain
Eisai Limited

Completed

A Study to Assess the Efficacy and Safety of Adjunctive Zonisamide in Paediatric Partial Onset Seizures (CATZ Extension Study)

Partial Seizures

Italy
Eisai Limited

Terminated

Evaluation of the Long-term Safety, Tolerability, and Efficacy of Perampanel (E2007) as an Adjunctive Therapy in Levodopa Treated Parkinson's Disease Subjects With Motor Fluctuations

Parkinson's Disease

France
Eisai Limited

Completed

Open Label, Zonegran (Zonisamide) In Partial Onset Seizures

Epilepsy

United Kingdom, France, Germany, Italy, Austria, Denmark, Norway
Eisai Limited

Completed

The Efficacy, Safety, And Tolerability Of Donepezil HCl (E2020) In Patients With CADASIL Who Have Cognitive Impairment

Cognitive Impairment

United States, Spain, Australia
Eisai Limited

Completed

The Efficacy, Safety and Tolerability of E2007 in Levodopa Treated Parkinson's Disease Patients With Motor Fluctuations

Parkinson's Disease

Poland, France, Spain, Germany, Hungary, Italy, Estonia, South Africa, Belgium, United Kingdom, Portugal, Austria, Czech Republic, Israel, Lithuania, Serbia, Sweden
Eisai Limited

Completed

Comparing The Effect On Cognition Of Adjunctive Therapy With Zonisamide Versus Sodium Valproate

Epilepsy

Finland, Austria
Eisai Inc.
Eisai Limited

Completed

A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine

Breast Cancer

United States, Canada
Eisai Limited

Terminated

An Open-label, Randomized, Phase II Study of the Efficacy and Safety of Indisulam (E7070) in Combination With Capecitabine

Metastatic Breast Cancer

Russian Federation, United Kingdom, Germany, Italy, Spain
Eisai Limited

Completed

An Electrophysiological Study Of E2014 In Healthy Adult Male Japanese And Caucasian Subjects

Spasmodic Torticollis

Japan
Eisai Inc.
Eisai Limited

Completed

A Study of E3810 With Pre- and Post-Treatment pH Monitoring in Patients With Non-Erosive Gastroesophageal Reflux Disease

Non-erosive Gastroesophageal Reflux Disease

Japan
Eisai Limited

Completed

A Multi-Center, Randomized, Double-Blind, Parallel Group Study With 3 Groups Receiving Placebo, 5 mg of E2020 and 10 mg of E2020

Alzheimer Disease

Japan

3

Subscribe